Suzanne Arulogun, MBBS, FRACP, FRCPA, University College London Hospitals NHS Foundation Trust, London, UK, shares the results of a retrospective cohort analysis which evaluated the impact of bendamustine-rituximab (BR) dose intensity on the outcomes of patients with Waldenström’s macroglobulinemia (WM). Results indicated that patients receiving a higher dose of BR demonstrated an improved progression-free survival (PFS), and Dr Arulogun further highlights the implications of these findings. This interview took place at the 11th International Workshop on Waldenström’s Macroglobulinemia (IWWM-11), held in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.